Portside Wealth Group LLC Invests $497,000 in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Portside Wealth Group LLC acquired a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the third quarter, HoldingsChannel reports. The fund acquired 5,352 shares of the medical instruments supplier’s stock, valued at approximately $497,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in LMAT. NBC Securities Inc. boosted its position in shares of LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 183 shares in the last quarter. GAMMA Investing LLC grew its stake in LeMaitre Vascular by 57.0% in the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock valued at $45,000 after acquiring an additional 199 shares during the period. West Oak Capital LLC bought a new stake in shares of LeMaitre Vascular in the second quarter worth about $58,000. USA Financial Formulas acquired a new stake in shares of LeMaitre Vascular during the third quarter worth about $60,000. Finally, nVerses Capital LLC raised its position in shares of LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after purchasing an additional 200 shares during the period. Institutional investors own 84.64% of the company’s stock.

Insiders Place Their Bets

In other news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the transaction, the director now owns 14,114 shares of the company’s stock, valued at $1,158,335.98. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 10.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on LMAT. JMP Securities increased their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 20th. Barrington Research increased their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective on the stock. StockNews.com upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, Oppenheimer reissued an “outperform” rating and issued a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $94.57.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT opened at $104.25 on Friday. The business has a 50-day moving average of $90.66 and a 200-day moving average of $84.27. The stock has a market capitalization of $2.34 billion, a price-to-earnings ratio of 56.97, a PEG ratio of 2.49 and a beta of 0.89. LeMaitre Vascular, Inc. has a fifty-two week low of $47.72 and a fifty-two week high of $104.81.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. During the same period last year, the company earned $0.33 earnings per share. The business’s revenue was up 15.6% compared to the same quarter last year. On average, sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.61%. The ex-dividend date of this dividend is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 34.97%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.